Anthera Pharmaceuticals, Inc.
ANTH
$0.00
$0.000.00%
OTC PK
| 03/31/2018 | 12/31/2017 | 09/30/2017 | 06/30/2017 | 03/31/2017 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | 0.00 | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 28.26M | 28.49M | 31.67M | 39.66M | 44.33M |
| Gross Profit | -28.26M | -28.49M | -31.67M | -39.66M | -44.33M |
| SG&A Expenses | 8.54M | 7.94M | 10.09M | 10.79M | 11.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.80M | 36.43M | 41.76M | 50.44M | 56.06M |
| Operating Income | -36.80M | -36.43M | -41.76M | -50.44M | -56.06M |
| Income Before Tax | -23.39M | -26.87M | -30.19M | -40.36M | -55.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.39 | -26.87 | -30.19 | -40.36 | -55.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.39M | -26.87M | -30.19M | -40.36M | -55.00M |
| EBIT | -36.80M | -36.43M | -41.76M | -50.44M | -56.06M |
| EBITDA | -36.40M | -36.15M | -41.49M | -50.12M | -55.83M |
| EPS Basic | -1.70 | -3.31 | -5.42 | -9.69 | -12.52 |
| Normalized Basic EPS | -1.02 | -1.78 | -2.85 | -4.47 | -6.23 |
| EPS Diluted | -1.70 | -3.31 | -5.42 | -9.69 | -12.52 |
| Normalized Diluted EPS | -1.02 | -1.78 | -2.85 | -4.47 | -6.23 |
| Average Basic Shares Outstanding | 56.44M | 41.03M | 33.15M | 27.41M | 22.41M |
| Average Diluted Shares Outstanding | 56.44M | 41.03M | 33.15M | 27.41M | 22.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |